Eosinophilic Esophagitis - Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020 - 2030

Eosinophilic Esophagitis (EoE) is defined as a chronic, immune-mediated, atopic inflammatory condition of the esophagus, recognized over the past two decades. In EoE, eosinophils infiltrate the esophagus, contributing to tissue damage and chronic inflammation. It is diagnosed by histologic analysis of ≥15 eosinophils per high power field (eos/hpf) in one or more esophageal biopsy specimens and exclusion of pathologic gastrointestinal reflux disease (GERD). EoE symptoms are similar to GERD, which is why the two conditions were thought to be the same for so long. The key to diagnosing EoE is that patients with EoE don't improve with GERD medications.

Key Highlights

• A large number of symptomatic treatments are currently used off-label. The most frequently used drug classes are proton pump inhibitors and corticosteroids.
• The main driver to growth in the EoE market is the introduction of high-priced biologics.
• The main barrier to growth in the EoE market is low diagnosis rates caused by limited disease awareness.
• The greatest unmet needs within the EoE market are lack of data, the need for more effective or curative therapies, increased awareness and education, and more options for the pediatric population.

EoE symptoms include -

• Children: Difficulty feeding, difficulty eating, vomiting, abdominal pain, decrease in appetite, dysphagia, food impaction, failure to thrive (poor growth, malnutrition, and weight loss). Children with EoE have a higher rate of atopy (asthma, eczema, or rhinitis) than children without EoE.
• Adults: Difficulty swallowing (dysphagia), food getting stuck in the esophagus after swallowing (impaction), chest pain that is often centrally located and does not respond to antacids, backflow of undigested food (regurgitation).

KEY QUESTIONS ANSWERED

• Which unmet needs are limiting the treatment of EoE in the US?
• What strategies can the pharmaceutical industry employ to increase treatment rates for EoE?
• What effect will the launch of generics have on the sales of branded agents?
• What are the main R&D trends in the EoE market and which companies are leading the way?
• Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

• Overview of EoE including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Topline EoE market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
• Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting EoE therapeutics sales in the US.
• Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the US EoE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the US EoE therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US EoE market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the US EoE therapeutics market from 2020-2030.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.